Evidence map›Paper›PMID 42041295›Full record

ArticleAntibiotics (Basel, Switzerland)2026

Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human

Liana C Chan, Hong K Lee, Ling Wang, Huiyuan Wang, Scott G Filler, Alexandra Ciranna, Wessam Abdelhady, Yan Q Xiong, Liang Li, Rachelle A Gonzales and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Liana C ChanHarbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA.ORCID 0000-0003-2567-4418
Hong K LeeHarbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA.
Ling WangHarbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA.
Huiyuan WangHarbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA.
Scott G FillerHarbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.
Alexandra CirannaDivision of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, NC 27708, USA.
Wessam AbdelhadyHarbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.
Yan Q XiongHarbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.
Liang LiHarbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.
Rachelle A GonzalesHarbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.
Felicia RuffinDivision of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, NC 27708, USA.ORCID 0000-0003-2176-6462
Vance G FowlerDivision of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, NC 27708, USA.
Arnold S BayerHarbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.ORCID 0000-0003-1968-0192
Richard A ProctorSchool of Medicine and Public Health, University of Wisconsin, Madison, WI 53726, USA.
Michael R YeamanHarbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA.
MRSA Systems Immunobiology Group (MSIG)

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Systems Epigenomics of Persistent Bloodstream InfectionU19AI172713 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Scott G Filler · 2023 to 2026
$11.6M
Systems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1M
NCATS NIH HHS KL2 TR001882NIAID NIH HHS U01 AI124319NIAID NIH HHS U19 AI172713
6 · The paper itself

Abstract

background

methodsIn this study, we assessed virulence phenotypes and mechanisms in persistent (PB) vs. resolving (RB) MRSA isolates from SAB.

resultsOverall, PB isolates caused less hemolysis or biofilm formation than RB isolates, but proteolysis was equivalent. Attenuation of these virulence phenotypes increased longitudinally during the course of SAB. Although PB vs. RB isolates had similar human endothelial cell invasion rates, PB isolates more frequently formed SCVs intracellularly and inversely correlated with pH. Study PB and RB isolates exhibited distinct susceptibilities to prototypic human host defense peptides (HDPs), which were influenced by antibiotics and pH. Furthermore, mechanistic signatures of HDPs differed between PB and RB isolates.

conclusionsTogether, these results reveal that MRSA isolates from PB vs. RB outcomes of SAB have differential virulence profiles that suggest coordinated immune subversion in PB. Understanding MRSA adaptations that promote persistence in SAB may enable innovative agents and strategies to address these challenging infections.

Indexed as

host defense peptideresistancesmall colony variantStaphylococcus aureusvirulence

Identifiers

PMID42041295
PMCPMC13113033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.